Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microbiome-derived ethanol in nonalcoholic fatty liver disease.
Meijnikman AS, Davids M, Herrema H, Aydin O, Tremaroli V, Rios-Morales M, Levels H, Bruin S, de Brauw M, Verheij J, Kemper M, Holleboom AG, Tushuizen ME, Schwartz TW, Nielsen J, Brandjes D, Dirinck E, Weyler J, Verrijken A, De Block CEM, Vonghia L, Francque S, Beuers U, Gerdes VEA, Bäckhed F, Groen AK, Nieuwdorp M. Meijnikman AS, et al. Among authors: tushuizen me. Nat Med. 2022 Oct;28(10):2100-2106. doi: 10.1038/s41591-022-02016-6. Epub 2022 Oct 10. Nat Med. 2022. PMID: 36216942
Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.
Schaapman JJ, Tushuizen ME, Coenraad MJ, Lamb HJ. Schaapman JJ, et al. Among authors: tushuizen me. J Magn Reson Imaging. 2021 Jun;53(6):1623-1631. doi: 10.1002/jmri.27292. Epub 2020 Aug 21. J Magn Reson Imaging. 2021. PMID: 32822095 Free PMC article. Review.
Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.
Theel W, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EFC, Kanhai DA, Apers J, van Dalen BM, de Knegt RJ, Holleboom AG, Tushuizen ME, Grobbee DE, Wiebolt J, Castro Cabezas M. Theel W, et al. Among authors: tushuizen me. Obes Rev. 2022 Aug;23(8):e13481. doi: 10.1111/obr.13481. Epub 2022 Jun 12. Obes Rev. 2022. PMID: 35692179 Review.
Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.
Grobbee EJ, de Jong VD, Schrieks IC, Tushuizen ME, Holleboom AG, Tardif JC, Lincoff AM, Schwartz GG, Castro Cabezas M, Grobbee DE. Grobbee EJ, et al. Among authors: tushuizen me. PLoS One. 2022 Nov 15;17(11):e0277706. doi: 10.1371/journal.pone.0277706. eCollection 2022. PLoS One. 2022. PMID: 36378671 Free PMC article. Clinical Trial.
92 results